Monogram presents the results of the first studies ETag Breast Cancer

Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that two presentations on the details of initial studies clinical benefits of its proprietary technology in 43 ETag metastatic breast cancer in American Society of Clinical Oncology (ASCO) (June 1 will be presented - 5) Chicago, Illinois. A third presentation describes the molecular characterization of cell lines that have acquired resistance to breast cancer drug Herceptin (trastuzumab).
is a highly advanced diagnostic platform for quantifying protein expression, protein-protein interactions (receptor dimerization, for example) and protein modification (phosphorylation, for example). This unique feature allows the technology to accurately assess ETag signaling pathways that control cell growth, proliferation andsurvival. Disruption of these pathways has been associated with a wide range of cancers, including breast, lung, prostate and colon-rectum.
various stages of this fundamental cell signaling pathways, a chance for the diagnostic possibilities of ETAG technology to deliver could improve patient care and drug development. To describe presentations at the ASCO conference, progress in the fight against Companys two central issues related to the treatment of HER2 () of patients with breast cancer. First, why do not all HER2 breast cancer () is also well to targeted therapy with Herceptin. And secondly HER2 breast cancer, most () resistant to treatment with Herceptin.
presentations are: - differential survival after treatment with trastuzumab based on quantitative HER2expression and HER2-HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer. (Poster 12 / Abstract 1025, presented Saturday, June 2nd 8:00-12: 24:00
requirements for concomitant chemotherapy (JJ5 Posters, Abstract 10557, presented Sunday, June 3rd 8:00 to 12:00, S Hall A2) - Patterns of HER-family receptor dimerization in trastuzumab susceptible and trastuzumab resistant cell lines (A3 Poster

Pages: [1] 2 3 4 

Input your comment:

Name:
Site url:	http://
Message:
Enter today's date, 2 digits (spam protection):